HC Wainwright Analysts Raise Earnings Estimates for NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Equities researchers at HC Wainwright boosted their Q2 2026 earnings per share estimates for shares of Nurix Therapeutics in a research note issued to investors on Wednesday, June 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.72) per share for the quarter, up from their previous estimate of ($0.73). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.94) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($2.59) EPS.

Other analysts have also recently issued reports about the company. Needham & Company LLC boosted their price target on Nurix Therapeutics from $26.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday. Jefferies Financial Group boosted their price target on Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday. Truist Financial boosted their price target on Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday. Wells Fargo & Company cut Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their price target for the stock from $28.00 to $25.00 in a research report on Monday. Finally, BTIG Research boosted their price target on Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.14.

Nurix Therapeutics Stock Up 11.0%

Shares of NRIX opened at $16.98 on Friday. The business’s 50 day moving average price is $16.39 and its 200-day moving average price is $16.92. Nurix Therapeutics has a 52 week low of $8.19 and a 52 week high of $22.50. The stock has a market cap of $1.76 billion, a P/E ratio of -5.37 and a beta of 1.86.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The company had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million.

Institutional Trading of Nurix Therapeutics

Large investors have recently modified their holdings of the company. Larson Financial Group LLC grew its holdings in shares of Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after acquiring an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management bought a new stake in shares of Nurix Therapeutics in the fourth quarter worth $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Nurix Therapeutics in the fourth quarter worth $33,000. KBC Group NV bought a new stake in shares of Nurix Therapeutics in the first quarter worth $34,000. Finally, Wexford Capital LP bought a new stake in shares of Nurix Therapeutics in the third quarter worth $41,000.

Insider Activity at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,214 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $16.65, for a total value of $53,513.10. Following the transaction, the insider directly owned 120,399 shares in the company, valued at $2,004,643.35. This trade represents a 2.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the sale, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at $624,027.20. The trade was a 27.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,657 shares of company stock worth $326,586 in the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.